Tianjin, China

Baohong Hou

This inventor holds 10 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Tianjin University, Hainan Lingkang Pharmaceutical Co., Ltd, Nantong Licheng Biological Engineering Co. Ltd. Active years: 2017-2025.

USPTO Granted Patents = 10 

% Patents Active = 60.0


 

Average Co-Inventor Count = 8.5

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Pioneering Innovations: The Inventor Baohong Hou

Introduction: Baohong Hou is a visionary inventor based in Tianjin, China, whose relentless pursuit of innovation has resulted in groundbreaking patents that have the potential to revolutionize various industries.

Latest Patents: Baohong Hou's latest patents include a unique crystalline form of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide with a large particle size, as well as a novel solvate of etoricoxib, both offering exceptional properties and applications in their respective fields.

Career Highlights: With a total of 8 patents to his name, Baohong Hou has established himself as a leading figure in the world of innovative research and development. His work spans across disciplines, showcasing his versatility and ingenuity.

Collaborations: Baohong Hou has collaborated with esteemed institutions such as Tianjin University and Hainan Lingkang Pharmaceutical Co., Ltd., where he has worked alongside talented individuals like Qiuxiang Yin and Junbo Gong, collectively contributing to the advancement of science and technology.

Conclusion: In conclusion, Baohong Hou stands as a beacon of innovation, with a proven track record of pioneering inventions that have the power to shape the future. His dedication to pushing the boundaries of knowledge and creativity continues to inspire the next generation of inventors and researchers worldwide.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…